PTC Therapeutics (NASDAQ:PTCT) Releases Quarterly Earnings Results, Beats Estimates By $0.42 EPS

Key Points

• PTC Therapeutics beat expectations in Q1, reporting adjusted EPS of -$0.03 versus estimates of -$0.45 and revenue of $272.6 million versus expectations of $218.8 million. Revenue rose 43.5% year over year.
• Management raised full-year guidance, now targeting $1.08 billion to $1.18 billion in total revenue and $750 million to $850 million in product revenue for 2026, reflecting stronger commercial momentum.
• Pipeline and launch progress remain important drivers, with Sephience revenue accelerating and positive interim data from votoplam supporting further clinical development, while the company also reported $1.89 billion in cash and investments to fund operations.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.42, FiscalAI reports. The business had revenue of $272.55 million during the quarter, compared to analysts' expectations of $218.80 million. PTC Therapeutics had a negative return on equity of 362.45% and a net margin of 39.44%.The company's revenue for the quarter was up 43.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $10.04 EPS.

Here are the key takeaways from PTC Therapeutics' conference call:

• Record quarter with $273M total revenue and $226M net product revenue; management raised 2026 product revenue guidance to $750M–$850M and total revenue to $1.08B–$1.18B.
• Sephience launch accelerating—Q1 Sephience revenue was $125M (36% QoQ), U.S. starts averaging ~140/month, >90% of U.S. PKU centers have prescribed, and commercial roll‑out is planned in up to 30 countries by year‑end with payers covering >2/3 of the U.S. population.
• Positive 24‑month PIVOT‑HD interim results for votoplam: the 10 mg dose showed a ~52% slowing of disease progression vs a matched natural history cohort in Stage 2 and a favorable safety profile, supporting the Novartis‑led phase III INVEST‑HD (≈770 pts) now enrolling.
• Vatiquinone path forward agreed with FDA: an open‑label, natural‑history‑controlled 24‑month study (≈120 patients, age 7–21, primary mFARS) will be initiated to support NDA resubmission, which management says increases probability of success but requires additional data collection.
• Strong liquidity with $1.89B in cash, cash equivalents and marketable securities as of March 31, 2026, which management says supports ongoing R&D, the Sephience launch, and selective accretive business development.

PTC Therapeutics Trading Up 14.3%

PTCT stock traded up $9.20 during mid-day trading on Friday, hitting $73.69. 5,836,355 shares of the company were exchanged, compared to its average volume of 1,252,004. The company has a market capitalization of $6.11 billion, a PE ratio of 9.52 and a beta of 0.53. The firm has a fifty day simple moving average of $67.69 and a 200 day simple moving average of $72.07. PTC Therapeutics has a twelve month low of $43.17 and a twelve month high of $87.50.

Trending Headlines about PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: PTC Therapeutics reported Q1 revenue of $273 million and EPS of -$0.03, beating Wall Street estimates on both the top and bottom line. Revenue was up 43.5% year over year, and the company said its updated results support a higher full-year 2026 outlook. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
• Positive Sentiment: The company raised FY 2026 revenue guidance to $1.1 billion-$1.2 billion, above the market’s prior expectation of about $1.0 billion, signaling stronger commercial momentum. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
• Positive Sentiment: Wells Fargo lifted its price target on PTCT from $86 to $95 and kept an Overweight rating, suggesting further upside if execution continues. Benzinga report on Wells Fargo price target increase
• Neutral Sentiment: Royal Bank of Canada raised its price target from $81 to $82 while maintaining a Sector Perform rating, indicating a more measured view than Wells Fargo despite still acknowledging some upside. Benzinga report on RBC price target increase
• Neutral Sentiment: Management also highlighted progress in its pipeline and programs, including Sephience launch growth and positive interim data for votoplam, which may support longer-term sentiment but is less immediately impactful than the earnings beat. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

Insiders Place Their Bets

In related news, CEO Matthew B. Klein sold 7,371 shares of the business's stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $69.36, for a total value of $511,252.56. Following the completion of the sale, the chief executive officer directly owned 387,082 shares of the company's stock, valued at $26,848,007.52. The trade was a 1.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Neil Gregory Almstead sold 52,003 shares of the firm's stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $69.04, for a total value of $3,590,287.12. Following the transaction, the insider owned 60,137 shares in the company, valued at $4,151,858.48. This trade represents a 46.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 126,492 shares of company stock valued at $8,634,621. 5.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On PTC Therapeutics

Several large investors have recently made changes to their positions in the company. Wellington Management Group LLP increased its stake in PTC Therapeutics by 4.8% during the 3rd quarter. Wellington Management Group LLP now owns 4,918,619 shares of the biopharmaceutical company's stock valued at $301,856,000 after buying an additional 224,481 shares during the period. Janus Henderson Group PLC increased its holdings in shares of PTC Therapeutics by 28.6% in the fourth quarter. Janus Henderson Group PLC now owns 4,851,332 shares of the biopharmaceutical company's stock valued at $368,587,000 after buying an additional 1,077,776 shares in the last quarter. State Street Corp increased its holdings in shares of PTC Therapeutics by 34.2% in the fourth quarter. State Street Corp now owns 4,206,126 shares of the biopharmaceutical company's stock valued at $319,497,000 after buying an additional 1,071,343 shares in the last quarter. Toronto Dominion Bank lifted its holdings in shares of PTC Therapeutics by 27.5% during the fourth quarter. Toronto Dominion Bank now owns 4,138,215 shares of the biopharmaceutical company's stock valued at $314,339,000 after purchasing an additional 891,690 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in PTC Therapeutics by 16.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,023,091 shares of the biopharmaceutical company's stock valued at $77,714,000 after buying an additional 146,682 shares in the last quarter.

Wall Street Analyst Weigh In

PTCT has been the topic of a number of research reports. TD Cowen raised shares of PTC Therapeutics from a "hold" rating to a "buy" rating and raised their target price for the company from $75.00 to $90.00 in a research note on Friday. Cantor Fitzgerald restated an "overweight" rating on shares of PTC Therapeutics in a research note on Friday, February 20th. Royal Bank Of Canada upped their target price on PTC Therapeutics from $81.00 to $82.00 and gave the stock a "sector perform" rating in a research report on Friday. Raymond James Financial started coverage on PTC Therapeutics in a research note on Friday, April 10th. They issued an "outperform" rating and a $108.00 target price for the company. Finally, Jefferies Financial Group downgraded PTC Therapeutics from a "buy" rating to a "hold" rating and dropped their target price for the company from $91.00 to $76.00 in a report on Monday, March 30th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $88.36.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company's research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC's approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.